Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Ibrutinib-rituximab safe and effective in the frontline for elderly MCL

Preetesh Jain • 1 Jul 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Rituximab

Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the Phase II trial (NCT01880567) investigating the combination of ibrutinib with rituximab for the frontline treatment of elderly patients with mantle cell lymphoma (MCL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Preetesh Jain

5:06
Trials of interest in the mantle cell lymphoma space at ASH 2023
Preetesh Jain • 8 Dec 2023
0:58
Future work in mantle cell lymphoma
Preetesh Jain • 15 Jun 2023
1:32
Selecting BTK inhibitors for patients with MCL
Preetesh Jain • 15 Jun 2023
1:18
The unmet needs of patients with MCL who relapse after CAR-T
Preetesh Jain • 15 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals